Panacea Index Logo

Command Palette

Search for a command to run...

A randomized controlled trial of Mindfulness-Based Cognitive Therapy (MBCT) versus treatment-as-usual (TAU) for chronic, treatment-resistant depression: study protocol.

BMC psychiatry
January 1, 1970
Mira B Cladder-Micus et al. (6 authors)
Comparative StudyJournal ArticleMulticenter StudyRandomized Controlled TrialResearch Support, Non-U.S. Gov'tHuman StudyClinical
Study Details

Study Goal

The researchers aimed to determine the effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) in reducing depressive symptoms in patients with chronic, treatment-resistant depression who had previously received antidepressant medication and psychological treatment.

Results Summary

The study found that MBCT was effective in reducing relapse in recurrent depression and lowering symptom levels in acute depression, though its effectiveness for chronic, treatment-resistant depression required further investigation through a large randomized controlled trial.

Population

Patients with chronic, treatment-resistant depression who had received antidepressant medication and cognitive behavioral therapy or interpersonal therapy.

Effective Dosage

Not specified

Duration

Not specified

Interactions

None mentioned

Extracted Claims (3)
InterventionDirectionEndpointPopulationDosageImpactClaim #
Mindfulness-Based Cognitive Therapy (MBCT)
decrease
relapse in recurrent depression
-
-
effective in reducing
#1
Mindfulness-Based Cognitive Therapy (MBCT)
decrease
symptom levels in acute depression
-
-
lowering
#2
Mindfulness-Based Cognitive Therapy (MBCT)
decrease
depressive symptoms
patients with chronic, treatment-resistant depression
-
effectiveness in reducing
#3
Abstract

BACKGROUND: Major depression is a common psychiatric disorder, frequently taking a chronic course. Despite provision of evidence-based treatments, including antidepressant medication and psychological treatments like cognitive behavioral therapy or interpersonal therapy, a substantial amount of patients do not recover. Mindfulness-Based Cognitive Therapy (MBCT) has been found to be effective in reducing relapse in recurrent depression, as well as lowering symptom levels in acute depression. The effectiveness of MBCT for chronic, treatment-resistant depression has only be studied in a few pilot trials. A large randomized controlled trial is necessary to examine the effectiveness of MBCT in reducing depressive symptoms in chronic, treatment-resistant depression. METHODS/DESIGN: A randomized-controlled trial is conducted to compare MBCT with treatment-as-usual (TAU). Patients with chronic, treatment-resistant depression who have received antidepressant medication and cognitive behavioral therapy or interpersonal therapy are included. Assessments take place at baseline and post intervention/TAU-period. The primary outcome are depressive symptoms. Secondary outcomes are: remission rates, quality of life, rumination, mindfulness skills and self-compassion. Patients in the TAU condition are offered to participate in the MBCT after the post TAU-period assessment. From all completers of the MBCT (MBCT condition and patients participating after the TAU-period), follow-up assessments are taken at three and six months after the completion of the MBCT. DISCUSSION: This trial will result in valuable information about the effectiveness of MBCT in chronic, treatment-resistant depressed patients who previously received antidepressant medication and psychological treatment. TRIAL REGISTRATION: trialregister.nl NTR4843, registered 14th October 2014.

Medical Subject Headings (MeSH)
AdolescentAdultAgedAntidepressive AgentsChronic DiseaseDepressive Disorder, MajorDepressive Disorder, Treatment-ResistantHumansMaleMiddle AgedMindfulnessQuality of LifeRecurrenceYoung AdultCognitive Behavioral Therapy
Study Links
Quality Scores
SafetyNot Assessed
Efficacy75/10
Quality85/10
Citation Metrics
Total Citations8
Citations/Year0.8
Relative Citation Ratio0.37
NIH Percentile20.1%
Research Impact Scores
APT Score0.50
Weight Score1.69
Normalized Score0.67
Related Supplements